WallStSmart

CareCloud, Inc. (CCLD)vsNovartis AG ADR (NVS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Novartis AG ADR generates 43971% more annual revenue ($56.69B vs $128.64M). NVS leads profitability with a 22.5% profit margin vs 6.2%. CCLD appears more attractively valued with a PEG of 0.31. NVS earns a higher WallStSmart Score of 51/100 (C-).

CCLD

Buy

51

out of 100

Grade: C-

Growth: 4.0Profit: 6.0Value: 8.7Quality: 4.5
Piotroski: 3/9Altman Z: 2.20

NVS

Buy

51

out of 100

Grade: C-

Growth: 4.0Profit: 9.0Value: 3.3Quality: 4.5
Piotroski: 4/9Altman Z: 1.96
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CCLDUndervalued (+65.8%)

Margin of Safety

+65.8%

Fair Value

$6.55

Current Price

$2.05

$4.50 discount

UndervaluedFair: $6.55Overvalued
NVSSignificantly Overvalued (-47.0%)

Margin of Safety

-47.0%

Fair Value

$93.29

Current Price

$137.16

$43.87 premium

UndervaluedFair: $93.29Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CCLD2 strengths · Avg: 9.0/10
PEG RatioValuation
0.3110/10

Growing faster than its price suggests

Revenue GrowthGrowth
16.4%8/10

16.4% revenue growth

NVS5 strengths · Avg: 9.4/10
Market CapQuality
$260.70B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
30.7%10/10

Every $100 of equity generates 31 in profit

Operating MarginProfitability
34.6%10/10

Strong operational efficiency at 34.6%

Profit MarginProfitability
22.5%9/10

Keeps 23 of every $100 in revenue as profit

Free Cash FlowQuality
$5.57B8/10

Generating 5.6B in free cash flow

Areas to Watch

CCLD4 concerns · Avg: 3.3/10
P/E RatioValuation
29.3x4/10

Moderate valuation

Market CapQuality
$87.11M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
6.2%3/10

6.2% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

NVS4 concerns · Avg: 3.3/10
Revenue GrowthGrowth
0.8%4/10

0.8% revenue growth

Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

Debt/EquityHealth
1.183/10

Elevated debt levels

PEG RatioValuation
3.222/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : CCLD

The strongest argument for CCLD centers on PEG Ratio, Revenue Growth. Revenue growth of 16.4% demonstrates continued momentum. PEG of 0.31 suggests the stock is reasonably priced for its growth.

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.

Bear Case : CCLD

The primary concerns for CCLD are P/E Ratio, Market Cap, Profit Margin. Debt-to-equity of 3.10 is elevated, increasing financial risk.

Bear Case : NVS

The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.

Key Dynamics to Monitor

CCLD profiles as a growth stock while NVS is a value play — different risk/reward profiles.

CCLD carries more volatility with a beta of 1.50 — expect wider price swings.

CCLD is growing revenue faster at 16.4% — sustainability is the question.

NVS generates stronger free cash flow (5.6B), providing more financial flexibility.

Bottom Line

CCLD scores higher overall (51/100 vs 51/100) and 16.4% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

CareCloud, Inc.

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

CareCloud, Inc., a healthcare information technology (IT) company, provides a suite of cloud-based solutions and related business services to healthcare providers and hospitals primarily in the United States. The company is headquartered in Somerset, New Jersey.

Visit Website →

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Want to dig deeper into these stocks?